"Could drug addiction treatment of the future be as simple as an on/off switch in the brain? A study in rats has found that stimulating a key part of the brain reduces compulsive cocaine-seeking and suggests the possibility of changing addictiv"...
Serious adverse reactions that may be associated with VIVITROL (naltrexone xr inj) therapy in clinical use include: severe injection site reactions, eosinophilic pneumonia, serious allergic reactions, unintended precipitation of opioid withdrawal, accidental opioid overdose and depression and suicidality.
The adverse events seen most frequently in association with VIVITROL (naltrexone xr inj) therapy for alcohol dependence (i.e., those occurring in ≥ 5% and at least twice as frequently with VIVITROL (naltrexone xr inj) than placebo) include nausea, vomiting, injection site reactions (including induration, pruritus, nodules and swelling), muscle cramps, dizziness or syncope, somnolence or sedation, anorexia, decreased appetite or other appetite disorders.
The adverse events seen most frequently in association with VIVITROL (naltrexone xr inj) therapy in opioid-dependent patients (i.e., those occurring in ≥ 2% and at least twice as frequently with VIVITROL (naltrexone xr inj) than placebo) were hepatic enzyme abnormalities, injection site pain, nasopharyngitis, insomnia, and toothache.
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In all controlled and uncontrolled trials during the premarketing development of VIVITROL (naltrexone xr inj) , more than 1100 patients with alcohol and/or opioid dependence have been treated with VIVITROL (naltrexone xr inj) . Approximately 700 patients have been treated for 6 months or more, and more than 400 for 1 year or longer.
Adverse Events Leading to Discontinuation of Treatment
In controlled trials of 6 months or less in alcohol-dependent patients, 9% of alcohol-dependent patients treated with VIVITROL (naltrexone xr inj) discontinued treatment due to an adverse event, as compared to 7% of the alcohol-dependent patients treated with placebo. Adverse events in the VIVITROL (naltrexone xr inj) 380 mg group that led to more dropouts than in the placebo-treated group were injection site reactions (3%), nausea (2%), pregnancy (1%), headache (1%), and suicide-related events (0.3%). In the placebo group, 1% of patients withdrew due to injection site reactions, and 0% of patients withdrew due to the other adverse events.
In a controlled trial of 6 months, 2% of opioid-dependent patients treated with VIVITROL (naltrexone xr inj) discontinued treatment due to an adverse event, as compared to 2% of the opioid-dependent patients treated with placebo.
Common Adverse Reactions
Table 1 lists all treatment-emergent clinical adverse reactions, regardless of causality, occurring in ≥ 5% of patients with alcohol dependence, for which the incidence was greater in the combined VIVITROL (naltrexone xr inj) group than in the placebo group. A majority of patients treated with VIVITROL (naltrexone xr inj) in clinical studies had adverse reactions with a maximum intensity of "mild" or "moderate".
Table 1: Treatment-emergent Adverse Reactions (Reactions
in ≥ 5% of patients with alcohol dependence treated with VIVITROL (naltrexone xr inj) and occurring
more frequently in the combined VIVITROL (naltrexone xr inj) group than in the placebo group)
|Body System||Adverse Reaction/Preferred Term||Placebo||Naltrexone for extended-release injectable suspension|
|N=214|| 400 mg
| 380 mg
| 190 mg
|Infections & Infestations||Pharyngitis)c||23||11||0||0||22||11||35||17||57||13|
|Psychiatric Disorders||Insomnia, sleep disorder||25||12||2||8||29||14||27||13||58||13|
|General Disorders & Administration Site Conditions||Any ISR||106||50||22||88||142||69||121||58||285||65|
|Injection site tenderness||83||39||18||72||92||45||89||42||199||45|
|Injection site induration||18||8||7||28||71||35||52||25||130||30|
|Injection site pain||16||7||0||0||34||17||22||10||56||13|
|Other ISR (primarily nodules, swelling)||8||4||8||32||30||15||16||8||54||12|
|Injection site pruritus||0||0||0||0||21||10||13||6||34||8|
|Injection site ecchymosis||11||5||0||0||14||7||9||4||23||5|
|Musculoskeletal & Connective Tissue Disorders||Arthralgia, arthritis, joint stiffness||11||5||1||4||24||12||12||6||37||9|
|Back pain, back stiffness||10||5||1||4||12||6||14||7||27||6|
|Skin & Subcutaneous Tissue Disorders||Rashg)||8||4||3||12||12||6||10||5||25||6|
|Nervous System Disorders||Headacheh)||39||18||9||36||51||25||34||16||94||21|
|Metabolism & Nutrition Disorders||Anorexia, appetite decreased NOS, appetite disorder NOS||6||3||5||20||30||14||13||6||48||11|
|a) Includes the preferred terms: diarrhea NOS; frequent bowel
movements; gastrointestinal upset; loose stools
b) Includes the preferred terms: abdominal pain NOS; abdominal pain upper; stomach discomfort; abdominal pain lower
c) Includes the preferred terms: nasopharyngitis; pharyngitis streptococcal; pharyngitis NOS
d) Includes the preferred terms: anxiety NEC; anxiety aggravated; agitation; obsessive compulsive disorder; panic attack; nervousness; post-traumatic stress
e) Includes the preferred terms: malaise; fatigue (these two comprise the majority of cases); lethargy; sluggishness
f) Includes the preferred terms: muscle cramps; spasms; tightness; twitching; stiffness; rigidity
g) Includes the preferred terms: rash NOS; rash papular; heat rash
h) Includes the preferred terms: headache NOS; sinus headache; migraine; frequent headaches
In the open-label, long-term safety study conducted in the US, the commonly-reported adverse reactions among the opioid-dependent patients in the study were similar to those commonly observed events in the alcohol-dependent populations in VIVITROL (naltrexone xr inj) clinical trials as displayed in Table 1, above. For example, injection site reactions of all types, nausea and diarrhea occurred in more than 5% of patients on VIVITROL (naltrexone xr inj) in the open-label study. In contrast, 48% percent, of the opioid-dependent patients had at least one adverse event in the "Infections and Infestations" Body System. Adverse Reactions/Preferred Terms of nasopharyngitis, upper respiratory tract infection, urinary tract infection, and sinusitis were most commonly reported.
In the placebo-controlled study in opioid-dependent patients conducted in Russia, the overall frequency of adverse events was lower than in the U.S. population described above. Table 2 lists treatment-emergent clinical adverse events, regardless of causality, occurring in ≥ 2% of patients with opioid dependence, for which the incidence was greater in the VIVITROL (naltrexone xr inj) group than in the placebo group. All adverse events were assessed as having a maximum intensity of "mild" or "moderate".
Table 2: Treatment-emergent Clinical Adverse Events (Events in ≥ 2% of patients with opioid dependence treated with VIVITROL (naltrexone xr inj) and occurring more frequently in the VIVITROL (naltrexone xr inj) group than in the placebo group)
|Body System||Adverse Event/Preferred Term|| Placebo
| VIVITROL 380 mg
|Investigations||Alanine aminotransferase increased||7||6||16||13|
|Aspartate aminotransferase increased||3||2||13||10|
|Infections and Infestations||Nasopharyngitis||3||2||9||7|
|General Disorders and Administration Site Conditions||Injection site pain||1||1||6||5|
|Nervous System Disorders||Headache||3||2||4||3|
In clinical trials, subjects on VIVITROL (naltrexone xr inj) had increases in eosinophil counts relative to subjects on placebo. With continued use of VIVITROL (naltrexone xr inj) , eosinophil counts returned to normal over a period of several months.
VIVITROL (naltrexone xr inj) 380 mg was associated with a decrease in platelet count. In clinical trials, alcohol-dependent patients treated with VIVITROL (naltrexone xr inj) experienced a mean maximal decrease in platelet count of 17.8 x 103/µL, compared to 2.6 x 103/µL in placebo patients.
After 24 weeks of treatment, opioid-dependent patients treated with VIVITROL (naltrexone xr inj) experienced a mean maximal decrease in platelet count of 62.8 x 103/µL, compared to 39.9 x 103/µL in placebo patients. In randomized controlled trials, VIVITROL (naltrexone xr inj) was not associated with an increase in bleeding-related adverse events.
Hepatic Enzyme Elevations
In short-term, controlled trials, in alcohol-dependent patients, the incidence of AST elevations associated with VIVITROL treatment was similar to that observed with oral naltrexone treatment (1.5% each) and slightly higher than observed with placebo treatment (0.9%).
In the 6-month controlled trial conducted in opioid-dependent subjects, 89% had a baseline diagnosis of hepatitis C infection, and 41% had a baseline diagnosis of HIV infection. There were frequently observed elevated liver enzyme levels (ALT, AST, and GGT); these were more commonly reported as adverse events in the VIVITROL (naltrexone xr inj) 380 mg group than in the placebo group. Patients could not enroll in this trial if they had a baseline ALT or AST value that was more than three times the upper limit of normal. More patients treated with VIVITROL (naltrexone xr inj) in this study experienced treatment-emergent elevations in transaminases to more than three times the upper limit of normal than patients treated with placebo. Shifts to more than three times the upper limit of normal occurred in 20% of patients treated with VIVITROL (naltrexone xr inj) as compared with 13% of placebo patients. Shifts in values of AST to more than three times the upper limit were also more common in the VIVITROL (naltrexone xr inj) (14%) arm compared with the placebo (11%) arm. Opioid-dependent patients treated with VIVITROL (naltrexone xr inj) experienced a mean maximal increase from baseline ALT levels of 61 IU/L compared with 48 IU/L in placebo patients. Similarly for AST, opioid-dependent patients treated with VIVITROL (naltrexone xr inj) experienced a mean maximal increase from baseline AST levels of 40 IU/L compared with 31 IU/L in placebo patients.
In short-term controlled trials in alcohol-dependent patients, more patients treated with VIVITROL 380 mg (11%) and oral naltrexone (17%) shifted from normal creatinine phosphokinase (CPK) levels before treatment to abnormal CPK levels at the end of the trials, compared to placebo patients (8%). In open-label trials, 16% of patients dosed for more than 6 months had increases in CPK. For both the oral naltrexone and VIVITROL (naltrexone xr inj) 380 mg groups, CPK abnormalities were most frequently in the range of 1-2 x ULN. However, there were reports of CPK abnormalities as high as 4x ULN for the oral naltrexone group, and 35 x ULN for the VIVITROL (naltrexone xr inj) 380 mg group. Overall, there were no differences between the placebo and naltrexone (oral or injectable) groups with respect to the proportions of patients with a CPK value at least three times the upper limit of normal. No factors other than naltrexone exposure were associated with the CPK elevations.
More opioid-dependent patients treated with VIVITROL (naltrexone xr inj) 380 mg (39%) shifted from normal creatinine phosphokinase (CPK) levels before treatment to abnormal CPK levels during the study as compared to patients treated with placebo (32%). There were reports of CPK abnormalities as high as 41.8 x ULN for the placebo group, and 22.1 x ULN for the VIVITROL (naltrexone xr inj) 380 mg group.
Other Events Observed During the VIVITROL (naltrexone xr inj) Clinical Studies
The following is a list of treatment-emergent adverse reactions reported by alcohol- and/or opioid-dependent subjects treated with VIVITROL (naltrexone xr inj) in all clinical trials. The listing does not include those events already listed in the previous tables or elsewhere in labeling, those events for which a drug cause was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life-threatening.
Blood and Lymphatic System Disorders - lymphadenopathy (including cervical adenitis), white blood cell count increased
Gastrointestinal Disorders - abdominal discomfort, colitis, constipation, flatulence, gastroesophageal reflux disease, gastrointestinal hemorrhage, hemorrhoids, pancreatitis acute, paralytic ileus, perirectal abscess
Hepatobiliary Disorders - cholecystitis acute, cholelithiasis
Immune System Disorders - seasonal allergy, hypersensitivity reaction (including angioneurotic edema and urticaria)
Infections and Infestations - bronchitis, gastroenteritis, laryngitis, pneumonia, sinusitis, tooth abscess, upper respiratory tract infection, urinary tract infection, advanced HIV disease in HIV-infected patients
Investigations - weight decreased, weight increased
Musculoskeletal and Connective Tissue Disorders -joint stiffness, muscle spasms, myalgia, pain in limb
Nervous System Disorders - cerebral arterial aneurysm, convulsions, disturbance in attention, dysgeusia, mental impairment, migraine, ischemic stroke, paresthesia
Pregnancy, Puerperium, and Perinatal Conditions - abortion missed
Psychiatric Disorders - abnormal dreams, agitation, alcohol withdrawal syndrome, euphoric mood, delirium, libido decreased
Respiratory, Thoracic, and Mediastinal Disorders - chronic obstructive pulmonary disease, dyspnea, pharyngolaryngeal pain, sinus congestion
Skin and Subcutaneous Tissue Disorders -night sweats, pruritus, sweating increased Vascular Disorders -deep venous thrombosis, hot flushes, pulmonary embolism
Hypersensitivity Reactions including Anaphylaxis
Hypersensitivity reactions including anaphylaxis have been reported during postmarketing surveillance.
Reports From Other Intramuscular Drug Products Containing Polylactide-co-glycolide (PLG) Microspheres
Retinal Artery Occlusion
Retinal artery occlusion after injection with another drug product containing polylactide-co-glycolide (PLG) microspheres has been reported very rarely during postmarketing surveillance. This event has been reported in the presence of abnormal arteriovenous anastomosis. No cases of retinal artery occlusion have been reported during VIVITROL (naltrexone xr inj) clinical trials or postmarketing surveillance. VIVITROL (naltrexone xr inj) should be administered by intramuscular (IM) injection into the gluteal muscle, and care must be taken to avoid inadvertent injection into a blood vessel [see DOSAGE AND ADMINISTRATION].
Read the Vivitrol (naltrexone xr inj) Side Effects Center for a complete guide to possible side effects
Patients taking VIVITROL may not benefit from opioid-containing medicines. Naltrexone antagonizes the effects of opioid-containing medicines, such as cough and cold remedies, antidiarrheal preparations and opioid analgesics.
Read the Vivitrol Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 11/8/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Vivitrol Information
Vivitrol - User Reviews
Vivitrol User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.